Effect of metoprolol combined with atorvastatin calcium in patients with chronic heart failure
-
摘要: 目的 探讨美托洛尔联合阿托伐他汀钙治疗慢性心力衰竭患者的效果。 方法 选取120例慢性心力衰竭患者,随机分为2组各60例。对照组在常规治疗基础上采用美托洛尔治疗,观察组在对照组基础上采用阿托伐他汀钙治疗。比较2组治疗前后的心功能指标变化、血浆超敏C反应蛋白(hs-CRP)水平及不良反应。 结果 观察组治疗总有效率显著高于对照组(P < 0.05)。观察组治疗后左室收缩末期内径(LVEDs)、左室舒张末期容量(EDV)低于对照组,左心室射血分数(LVEF)高于对照组,血浆hs-CRP水平低于对照组,差异均有统计学意义(P < 0.05)。2组不良反应发生率比较无显著差异(P > 0.05)。 结论 美托洛尔联合阿托伐他汀钙治疗慢性心力衰竭效果显著,可改善患者心功能,降低血浆hs-CRP水平,且无明显不良反应。Abstract: Objective To investigate the therapeutic effect of metoprolol combined with atorvastatin calcium in patients with chronic heart failure. Methods A total of 120 patients with chronic heart failure treated in our hospital were selected and randomly divided into two groups. The control group(n=60)was given metoprolol based on routine treatment, and the observation group(n=60)was treated by atorvastatin calcium treatment on the basis of the control group. Cardiac function indexes and plasma high sensitivity C reactive protein(hs-CRP)and adverse reactions before and after treatment in the two groups were compared. Results The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant(P < 0.05). After treatment, the left ventricular end-systolic diameter(LVEDs), left ventricular end-diastolic volume(EDV)in the observation group were lower than those in the control group, left ventricular ejection fraction(LVEF)was higher than that in the control group, and plasma hs-CRP was lower than that in the control group(P < 0.05). There were no differences in adverse reactions between the two groups(P > 0.05). Conclusion Metoprolol combined with atorvastatin calcium has a significant effect on chronic heart failure, with significant improvement in cardiac function and a decrease in hs-CRP, and no obvious side effects are found.
-
-
Chuquiure-Valenzuela E, Fiscal-López O, García-Romero D, et al. Clinimetric analysis of heart failure in Mexican patients[J]. Arch Cardiol Mex, 2019, 89(4): 339-347.
陈莉, 逯伟达, 吴媛媛, 等. 沙库巴曲缬沙坦对射血分数降低的心力衰竭Ⅳ级患者生化指标和左心室结构的干预作用[J]. 中华老年医学杂志, 2019, 38(5): 525-528. 文芳梅, 单梓梅, 高爽. 老年慢性心力衰竭患者NT-ProBNP、hs-CRP、IL-10水平与心功能相关性研究[J]. 武警医学, 2016, 27(8): 796-799. 张淑平, 李永强, 刘宏颖, 等. 小剂量阿托伐他汀钙辅助治疗对冠心病合并心力衰竭患者血清脑钠肽水平及心功能的影响[J]. 安徽医药, 2018, 22(10): 2011-2014. 强钰伟, 杨美艳, 徐勇, 等. 琥珀酸美托洛尔缓释片对老年慢性心力衰竭患者心功能及自主神经张力的影响[J]. 解放军医学院学报, 2016, 37(7): 701-703. 中华医学会心血管病学分会, 中国医师协会心力衰竭专业委员会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(10): 760-789. Araiza-Garaygordobil D, Fuentes-Mendoza A, Guerrero-Pando C, et al. Heart failure with preserved ejection fraction: the dark side of an old disease[J]. Arch Cardiol Mex, 2019, 89(4): 360-368
Di Lenarda A, Colivicchi F, Gabrielli D. Heart failure hospitalization: a critical event that may become a clinical opportunity[J]. G Ital Cardiol(Rome), 2019, 20(12): 690-693.
陈玲, 赵虹. 比索洛尔辅治老年心力衰竭的疗效及对血浆中NT-proBNP和hs-CRP水平的影响[J]. 医学综述, 2016, 22(3): 569-572. 柯子立, 陈芬, 陈志强, 等. 琥珀酸美托洛尔缓释片与酒石酸美托洛尔片治疗慢性心力衰竭临床疗效的Meta分析[J]. 实用心脑肺血管病杂志, 2016, 24(9): 1-5. 张楠, 王玉通, 李鲲鹏, 等. β受体阻滞剂卡维地洛、美托洛尔对心力衰竭大鼠 体液因子及ANP、TNF -α、IL-6、NE的影响分析[J]. 河北医科大学学报, 2018, 39(9): 1081-1084. 汤毅. 利心丸联合美托洛尔治疗心力衰竭的临床研究[J]. 现代药物与临床, 2019, 34(6): 1653-1656. 王志肖, 梁芝萍, 于同德. 活血益心汤联合阿托伐他汀钙片对慢性心力衰竭患者N末端B型脑钠肽前体及QT离散度的影响[J]. 国际中医中药杂志, 2018, 40(3): 201-204. 方玲, 李冠兰, 李云, 等. 贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床疗效[J]. 现代生物医学进展, 2017, 17(11): 2102-2105. 胡勇钧, 唐哨勇, 陈姣, 等. 缬沙坦或贝那普利联合阿托伐他汀治疗慢性心力衰竭的临床研究[J]. 中国临床药理学杂志, 2016, 32(4): 291-293. 丁鹏, 李春娟. β受体阻滞剂联合他汀类药物治疗慢性心力衰竭临床观察[J]. 陕西医学杂志, 2017, 46(2): 264-264. 高晓燕, 刘东兴, 赵洪磊. 利尿合剂治疗慢性心力衰竭患者的血清hs-CRP、IL-6、BNP水平变化及临床意义[J]. 山东医药, 2016, 56(33): 68-70. 李宏宇, 魏仲航. 检测血浆NT-proBNP、hs-CRP、CTnT水平对慢性心力衰竭的临床价值[J]. 中国实验诊断学, 2016, 20(9): 1535-1536. -
期刊类型引用(1)
1. 万姜维，成东茹，王涛，高萍. 血清乳酸脱氢酶、β_2微球蛋白、铁蛋白联合改良WHO预后积分系统预测骨髓增生异常综合征预后不良的价值. 实用临床医药杂志. 2024(05): 79-84 . 
本站查看
其他类型引用(0)
计量
- 文章访问数: 549
- HTML全文浏览量: 119
- PDF下载量: 15
- 被引次数: 1
下载:
苏公网安备 32100302010246号